| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| Domain | SH3_2 | 6.03e-04 | 86 | 36 | 3 | IPR011511 | |
| Domain | SH3_2 | 6.03e-04 | 86 | 36 | 3 | PF07653 | |
| Domain | MYOSIN_MOTOR | 2.43e-03 | 38 | 36 | 2 | PS51456 | |
| Domain | Myosin_head | 2.43e-03 | 38 | 36 | 2 | PF00063 | |
| Domain | Myosin_head_motor_dom | 2.43e-03 | 38 | 36 | 2 | IPR001609 | |
| Domain | MYSc | 2.43e-03 | 38 | 36 | 2 | SM00242 | |
| Domain | RhoGAP | 6.35e-03 | 62 | 36 | 2 | SM00324 | |
| Domain | RhoGAP | 6.55e-03 | 63 | 36 | 2 | PF00620 | |
| Domain | RHOGAP | 6.76e-03 | 64 | 36 | 2 | PS50238 | |
| Domain | RhoGAP_dom | 6.76e-03 | 64 | 36 | 2 | IPR000198 | |
| Domain | - | 6.76e-03 | 64 | 36 | 2 | 1.10.555.10 | |
| Domain | SH3 | 8.22e-03 | 216 | 36 | 3 | PS50002 | |
| Domain | SH3 | 8.22e-03 | 216 | 36 | 3 | SM00326 | |
| Domain | SH3_domain | 8.65e-03 | 220 | 36 | 3 | IPR001452 | |
| Domain | Rho_GTPase_activation_prot | 1.25e-02 | 88 | 36 | 2 | IPR008936 | |
| Domain | IQ_motif_EF-hand-BS | 1.30e-02 | 90 | 36 | 2 | IPR000048 | |
| Domain | IQ | 1.38e-02 | 93 | 36 | 2 | PS50096 | |
| Pathway | REACTOME_RHOV_GTPASE_CYCLE | 5.80e-05 | 37 | 29 | 3 | M41819 | |
| Pathway | REACTOME_RHOV_GTPASE_CYCLE | 5.80e-05 | 37 | 29 | 3 | MM15610 | |
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | BDP1 CHD9 KATNIP ZFHX3 ZNF236 NFAT5 MYO9A ADCY3 RALGPS1 SBF2 | 2.43e-06 | 1489 | 37 | 10 | 28611215 |
| Pubmed | 3.30e-06 | 3 | 37 | 2 | 19640849 | ||
| Pubmed | 3.64e-06 | 98 | 37 | 4 | 34943047 | ||
| Pubmed | Dosage-dependent requirement for mouse Vezf1 in vascular system development. | 3.97e-06 | 29 | 37 | 3 | 15882861 | |
| Pubmed | Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks. | 5.98e-06 | 111 | 37 | 4 | 22558309 | |
| Pubmed | 6.60e-06 | 4 | 37 | 2 | 31484922 | ||
| Pubmed | Serum response factor is required for sprouting angiogenesis and vascular integrity. | 1.33e-05 | 43 | 37 | 3 | 18804439 | |
| Pubmed | Activation of rapid oestrogen signalling in aggressive human breast cancers. | 1.65e-05 | 6 | 37 | 2 | 23065768 | |
| Pubmed | 1.65e-05 | 6 | 37 | 2 | 21355089 | ||
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | 3.00e-05 | 861 | 37 | 7 | 36931259 | |
| Pubmed | Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient mice. | 3.95e-05 | 9 | 37 | 2 | 15579434 | |
| Pubmed | 3.95e-05 | 9 | 37 | 2 | 21042317 | ||
| Pubmed | An organelle-specific protein landscape identifies novel diseases and molecular mechanisms. | 6.13e-05 | 1321 | 37 | 8 | 27173435 | |
| Pubmed | 6.86e-05 | 407 | 37 | 5 | 12693553 | ||
| Pubmed | Voltage-dependent conformational changes of Kv1.3 channels activate cell proliferation. | 7.03e-05 | 208 | 37 | 4 | 33230847 | |
| Pubmed | 7.22e-05 | 12 | 37 | 2 | 22363445 | ||
| Pubmed | Pathway analysis in HEK 293T cells overexpressing HIV-1 tat and nucleocapsid. | 8.53e-05 | 13 | 37 | 2 | 19884766 | |
| Pubmed | TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation. | 8.73e-05 | 220 | 37 | 4 | 35785414 | |
| Pubmed | The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. | 1.15e-04 | 15 | 37 | 2 | 15107403 | |
| Pubmed | Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. | 1.15e-04 | 15 | 37 | 2 | 21606590 | |
| Pubmed | The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. | 1.48e-04 | 17 | 37 | 2 | 16107612 | |
| Pubmed | Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. | 1.48e-04 | 17 | 37 | 2 | 20570966 | |
| Pubmed | 1.57e-04 | 486 | 37 | 5 | 20936779 | ||
| Pubmed | Chloride intracellular channel 4 is required for maturation of the cerebral collateral circulation. | 1.67e-04 | 18 | 37 | 2 | 26276819 | |
| Pubmed | 1.68e-04 | 493 | 37 | 5 | 15368895 | ||
| Pubmed | Proximity interactions among centrosome components identify regulators of centriole duplication. | 1.72e-04 | 101 | 37 | 3 | 24613305 | |
| Pubmed | 1.94e-04 | 808 | 37 | 6 | 20412781 | ||
| Pubmed | 2.26e-04 | 282 | 37 | 4 | 23667531 | ||
| Pubmed | Ascending Vasa Recta Are Angiopoietin/Tie2-Dependent Lymphatic-Like Vessels. | 2.75e-04 | 23 | 37 | 2 | 29237738 | |
| Pubmed | E-cadherin interactome complexity and robustness resolved by quantitative proteomics. | 3.15e-04 | 565 | 37 | 5 | 25468996 | |
| Pubmed | 3.60e-04 | 1285 | 37 | 7 | 35914814 | ||
| Pubmed | Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability. | 3.79e-04 | 588 | 37 | 5 | 38580884 | |
| Pubmed | 4.09e-04 | 28 | 37 | 2 | 24880616 | ||
| Pubmed | 4.70e-04 | 30 | 37 | 2 | 23349620 | ||
| Pubmed | 6.05e-04 | 34 | 37 | 2 | 26120030 | ||
| Pubmed | A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning. | 7.34e-04 | 1038 | 37 | 6 | 26673895 | |
| Pubmed | Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach. | 7.56e-04 | 38 | 37 | 2 | 16263699 | |
| Pubmed | 8.37e-04 | 40 | 37 | 2 | 28805822 | ||
| Pubmed | 8.76e-04 | 708 | 37 | 5 | 39231216 | ||
| Pubmed | Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. | 9.23e-04 | 42 | 37 | 2 | 11439183 | |
| Pubmed | Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics. | 1.03e-03 | 422 | 37 | 4 | 27342126 | |
| Coexpression | KANG_DOXORUBICIN_RESISTANCE_DN | 2.47e-06 | 19 | 37 | 3 | M3323 | |
| CoexpressionAtlas | Myeloid Cells, DC.8-4-11b-.MLN, CD11b-FITC CD4-PE CD11c-Alexa750 CD8a-PacificBlue, Lymph Node, avg-2 | 5.42e-05 | 403 | 36 | 6 | GSM605834_500 | |
| CoexpressionAtlas | Myeloid Cells, DC.8-4-11b-.MLN, CD45-APC CD11b-FITC CD11c-eFluor780 CD4-PE CD8a-eF, Lymph Node, avg-3 | 6.63e-05 | 418 | 36 | 6 | GSM605836_500 | |
| ToppCell | mild-MAIT|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 6.25e-07 | 199 | 37 | 5 | cbe1fb6d2c5fca7a1baf1ad20afcdf8e8e11bd84 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-G-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 9.28e-06 | 160 | 37 | 4 | 0293b244c063a62819690bf22bbc2681f8d15252 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-G|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 9.28e-06 | 160 | 37 | 4 | 3eaae86fa08f7651021316f8e5811bf48055591e | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.41e-05 | 178 | 37 | 4 | 01dafd19de04eff459253eaa9a35debf8f3deedf | |
| ToppCell | 343B-Lymphocytic-CD4_T-cell-Treg_cell_4|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.44e-05 | 179 | 37 | 4 | c09c3eed43d1aa3b7aa8f3021e6f2737840cde16 | |
| ToppCell | facs-Lung-EPCAM-24m-Mesenchymal-Pericyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.57e-05 | 183 | 37 | 4 | 0e8fb371d8eac777451c76f41d53577f5dfb740d | |
| ToppCell | facs-Lung-EPCAM-24m-Mesenchymal-pericyte_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.57e-05 | 183 | 37 | 4 | cbc3b00faa7e4e0dbbbc8ee105467c65241c7470 | |
| ToppCell | E17.5-Mesenchymal-myocytic_cell-vascular_associated_smooth_muscle_cell|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.71e-05 | 187 | 37 | 4 | 0dee138738b65531ff134a125b92234b5d0a653c | |
| ToppCell | P03-Mesenchymal-myocytic_cell-vascular_associated_smooth_muscle_cell|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.79e-05 | 189 | 37 | 4 | b5439ef221106f6d54434f268485e9bb17b39102 | |
| ToppCell | facs-Lung-nan-3m-Mesenchymal-pulmonary_interstitial_fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.82e-05 | 190 | 37 | 4 | c7bd087f36321cec61b98657433b4d19d135791f | |
| ToppCell | facs-Lung-nan-3m-Mesenchymal-Myofibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.82e-05 | 190 | 37 | 4 | 834218fcc59df5e7e52de154272f3d55d81d0dac | |
| ToppCell | facs-Brain_Non-Myeloid-Hippocampus-3m-Mesenchymal|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.90e-05 | 192 | 37 | 4 | e5117cdb8af220f60bd1410262078c0306667b4a | |
| ToppCell | Control-Endothelial-Endothelial-Gen_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.94e-05 | 193 | 37 | 4 | e1d546165dcc2392f540162206852c4717d7306f | |
| ToppCell | droplet-Limb_Muscle-MUSCLE|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.98e-05 | 194 | 37 | 4 | e3d63874111d1e8da3977329426e4dcf68d6de87 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.02e-05 | 195 | 37 | 4 | 6e875c83f838241b5fcaf4a3249b1408d74521dc | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Myeloid-Macrophage-macrophage,_alveolar-Macro_c3-EREG|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.06e-05 | 196 | 37 | 4 | 80264c2fbd94418f981085fed7c5bdda1e6f404c | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Mesenchymal-Pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.06e-05 | 196 | 37 | 4 | 184104cbea0461dd2757668ab9755948ac7b585a | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Mesenchymal|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.06e-05 | 196 | 37 | 4 | bebb20dc210576101c317011e3afb59798f5d255 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Mesenchymal-brain_pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.06e-05 | 196 | 37 | 4 | 8114e98923096c54b6834f21550c3061bab6773d | |
| ToppCell | 5'-Adult-SmallIntestine-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.06e-05 | 196 | 37 | 4 | ce6f7ddb8104471dc90347f427486379914d63b4 | |
| ToppCell | 5'-Adult-SmallIntestine-Mesenchymal-Pericytes|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.06e-05 | 196 | 37 | 4 | 6d7179decea512dd49bb2d5f6a4f5989349d52a9 | |
| ToppCell | COVID-19|World / Condition, Lineage and Cell class | 2.10e-05 | 197 | 37 | 4 | 228f641d79282cc3dc51b95a1f4b0cccfc200735 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Lymphocytic-T-T_CD4-CD4_TRM/EMRA|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.19e-05 | 199 | 37 | 4 | 5a29db2610ba06a2248325a16cad755d20debf2c | |
| ToppCell | control-Epithelial-Secretory|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.19e-05 | 199 | 37 | 4 | 3d01f90ffd271ca00129192787e4921bdca7e01e | |
| ToppCell | LPS_anti-TNF-Mesenchymal_myocytic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.23e-05 | 200 | 37 | 4 | 67dcbd86fbc79fd585d0793f979e4aac100326c9 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_myocytic|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 2.23e-05 | 200 | 37 | 4 | f599e4b051ac3dad11ad437e98dc8ea6754cca53 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c09-GZMK-FOS_l|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.45e-04 | 147 | 37 | 3 | 48d72b6770cd029dd299676e5d83e6ac62102049 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c4-CD14-CD16|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.50e-04 | 148 | 37 | 3 | fd0d8386b94adb1bdc993fbb44d2d87852bfd7f0 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Myocytic|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.91e-04 | 156 | 37 | 3 | 6365b69ede98bc866e996bc52736b00401aacf6f | |
| ToppCell | 10x5'-lymph-node_spleen-Myeloid_Mac-Intermediate_macrophages|lymph-node_spleen / Manually curated celltypes from each tissue | 3.43e-04 | 165 | 37 | 3 | c3fa9225d2f9c9e821d4fbd2315fcc98ce1f1c55 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_0|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.75e-04 | 170 | 37 | 3 | 7bba77ae34a0259fad6ee98cf665ff50f77a1328 | |
| ToppCell | E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_prolif|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.75e-04 | 170 | 37 | 3 | 1f994b690e881106a5d54b3080ccce6260bc3ac5 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_0|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 3.75e-04 | 170 | 37 | 3 | a43b977a7fe745536cf96b7c080397d9fa73086b | |
| ToppCell | facs|World / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.81e-04 | 171 | 37 | 3 | c9990bc041a632b2f7bbebbfe737772c423d7027 | |
| ToppCell | 10x5'-GI_small-bowel-Myeloid_Monocytic|GI_small-bowel / Manually curated celltypes from each tissue | 3.81e-04 | 171 | 37 | 3 | 098a7fd387357c0d4e1a6169af4d24ef95b30018 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.88e-04 | 172 | 37 | 3 | 3f784aed340b50ddbec3f7dc0a5279180d38a2bb | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-MAIT|Multiple_Sclerosis / Disease, Lineage and Cell Type | 3.88e-04 | 172 | 37 | 3 | 18bda0038cb37da6784e7bf7291272c108cfd9c5 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 3.94e-04 | 173 | 37 | 3 | efb8072475000888efe088d00e870c56ffad4172 | |
| ToppCell | facs-Lung-24m-Mesenchymal-myofibroblast|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.01e-04 | 174 | 37 | 3 | a7ade7372e83edd4e3983e77f8417b51f0b47340 | |
| ToppCell | 10x5'-GI_small-bowel-Myeloid_Monocytic-Classical_monocytes|GI_small-bowel / Manually curated celltypes from each tissue | 4.01e-04 | 174 | 37 | 3 | 05d54a36772f096047521e16a89cc42ae48d2a1d | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 4.01e-04 | 174 | 37 | 3 | 58300d64d3b6fd9ba1b6c87ea83b2777eb6be2f4 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.08e-04 | 175 | 37 | 3 | 1799a7be623dc3bf53ba580a7c47d2619969d708 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-14|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.08e-04 | 175 | 37 | 3 | 87e557f7508c88b2087db5d57e77d5e2c92ca083 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.08e-04 | 175 | 37 | 3 | 316f2ea930437bf1243b1c0f45e6bd864112c6f2 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.08e-04 | 175 | 37 | 3 | a9f08e1e4c2997dcdd3e5d92daac480da19100b8 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-T_mait-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.08e-04 | 175 | 37 | 3 | cc2428150987911d0d382e8177918724aa69f85c | |
| ToppCell | droplet-Heart-nan-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.15e-04 | 176 | 37 | 3 | 749b47eac5436fa34e0d243ffbc6f1897f4e431e | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-T_mait|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.15e-04 | 176 | 37 | 3 | 003076f1a983409ddf31b9c19e61c1facdd72566 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.15e-04 | 176 | 37 | 3 | 5e46a09a36b9645b1b1fcb0b64bd0898561af3a9 | |
| ToppCell | LPS-IL1RA+antiTNF|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.22e-04 | 177 | 37 | 3 | b7fee75de7e96924af488a5baa2334711889ae7c | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.22e-04 | 177 | 37 | 3 | 14fb8d182775dfd0e49aa7e4e12543a85b3b8bd6 | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_NK-T_mait-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.22e-04 | 177 | 37 | 3 | 605f71515c877bb4de4121675ec8c1318a2500a7 | |
| ToppCell | CV-Severe-7|Severe / Virus stimulation, Condition and Cluster | 4.22e-04 | 177 | 37 | 3 | 82fdd6185b368f54f03de389427cbe3071d21a99 | |
| ToppCell | IIF-Lymphocyte-T_NK-MAIT|IIF / Disease, Lineage and Cell Type | 4.29e-04 | 178 | 37 | 3 | be777ebef8f09a1a16fcee8fc69a65ab295b6e1d | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_reg-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.29e-04 | 178 | 37 | 3 | 90dedb3cef9b01907b9f8eec64218d6d2072be1f | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_reg|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.29e-04 | 178 | 37 | 3 | d6312286bf6cc5b107ccd7adb583d9667d4e1d21 | |
| ToppCell | droplet-Lung-LUNG-30m-Mesenchymal-pericyte_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.36e-04 | 179 | 37 | 3 | bfc226bcf0b93525992344f968268a261d86fcbf | |
| ToppCell | droplet-Lung-LUNG-30m-Mesenchymal-Pericyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.36e-04 | 179 | 37 | 3 | 36ad18f52e175ab636ceaa3be81212fa362c96c1 | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.36e-04 | 179 | 37 | 3 | 56db12467b445f2b8ef92af50779eeab10413eb2 | |
| ToppCell | LA-01._Fibroblast_I|LA / Chamber and Cluster_Paper | 4.36e-04 | 179 | 37 | 3 | dcb6ec9ae72b13fe388b72dace2815293fafe8ee | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.43e-04 | 180 | 37 | 3 | 92fb01b91261b3103454924cde56add337b41844 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_NK|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 4.43e-04 | 180 | 37 | 3 | 1c8398342d3fa4d5ca9a8a63626cc497c5291446 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_NK-T_mait|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.43e-04 | 180 | 37 | 3 | e53e9f3ebd48fb8237515e740ba5d9880ed6ade3 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_NK-T_NK-CD56_bright_NK|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 4.43e-04 | 180 | 37 | 3 | ddbab26b05f057bd78b78773381cd447bd2e2726 | |
| ToppCell | Control-Fibroblasts-Airway_smooth_muscle|Control / group, cell type (main and fine annotations) | 4.43e-04 | 180 | 37 | 3 | d0de12749ef0f51f0931c6e7b9b99966bdbc3ec1 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_NK-T_NK|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 4.43e-04 | 180 | 37 | 3 | 0a98d21fec67a890e75ebf0e2d23adddd77da214 | |
| ToppCell | normal-na-Lymphocytic_NK-T_mait-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 4.43e-04 | 180 | 37 | 3 | e66a8a61b3576ac37de7c559d16d4ed4f7a2fc78 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_NK-T_mait-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.43e-04 | 180 | 37 | 3 | 9d18aa1044945fe6481ea3284037a777657fd837 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_2|368C / Donor, Lineage, Cell class and subclass (all cells) | 4.43e-04 | 180 | 37 | 3 | 551b8de8d933d11bcd3897aeb2fd033355f958e2 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.50e-04 | 181 | 37 | 3 | 6a6bd8e020cb0929b6ecdcb55d467ad24fecfaf0 | |
| ToppCell | droplet-Marrow-nan-3m-Hematologic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.57e-04 | 182 | 37 | 3 | 1710eab3037a87609d21838be2d2d29c3bc36651 | |
| ToppCell | 3'-Broncho-tracheal-Mesenchymal-Mesenchymal_Myocytic-tracheobronchial_smooth_muscle_cell-SM_activated_stress_response|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.57e-04 | 182 | 37 | 3 | 1c1a687f728341c209b048b6715bcddd0ac20069 | |
| ToppCell | Pericytes-Cryobiopsy_01|World / lung cells shred on cell class, cell subclass, sample id | 4.57e-04 | 182 | 37 | 3 | 46c213597445b1f4f09dc367f27702d24b201daf | |
| ToppCell | droplet-Marrow-nan-3m-Hematologic-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.57e-04 | 182 | 37 | 3 | e78ba2c5cae480c16a596ce7c3bf2d480becacf4 | |
| ToppCell | 3'-Broncho-tracheal-Mesenchymal-Mesenchymal_Myocytic-tracheobronchial_smooth_muscle_cell-SM_activated_stress_response-SM_activated_stress_response_L.2.3.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.57e-04 | 182 | 37 | 3 | 97bb07478f56a937b490fba121ee603db64134a1 | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex-24m-Mesenchymal|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.57e-04 | 182 | 37 | 3 | ffe500d78a89dc6b4d05bab1664e7f30c94fb8d9 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c11-MKI67-FOS|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.65e-04 | 183 | 37 | 3 | ba7753e9fe2a6a87c5264f299ac97da2ddbda178 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 4.65e-04 | 183 | 37 | 3 | ff751a97466807bf04b5a0740138c61e298cd1fc | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.65e-04 | 183 | 37 | 3 | e84539978ab4de42e19186aed00f24bb50cbc21f | |
| ToppCell | droplet-Lung-30m-Mesenchymal-myofibroblast-pericyte_cell-pericyte|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.72e-04 | 184 | 37 | 3 | 7128a2be291544d3df3ed6c80f21ddda8437dcba | |
| ToppCell | droplet-Lung-30m-Mesenchymal-myofibroblast-pericyte_cell|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.72e-04 | 184 | 37 | 3 | d14238f7b0b55a4c8d7040bea854bd221a66ac30 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.72e-04 | 184 | 37 | 3 | 689a8af81a79a4bb3123cfa01958c953eab5de98 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.72e-04 | 184 | 37 | 3 | da06ff24ee2b2cf4715fdfce43030b2da9e0aaf8 | |
| ToppCell | P28-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 4.72e-04 | 184 | 37 | 3 | 23c24ab5786af33d605bc445d06117b9da6c6331 | |
| ToppCell | droplet-Lung-30m-Mesenchymal-myofibroblast|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.72e-04 | 184 | 37 | 3 | 55dde9c4eebac2a33788c1ff1d8fe312d150fad4 | |
| ToppCell | 356C-Lymphocytic-CD8+_Cytotoxic_T-cell|356C / Donor, Lineage, Cell class and subclass (all cells) | 4.72e-04 | 184 | 37 | 3 | 5b4f18b26d03e8e5798cac70d124534749fc4cc0 | |
| ToppCell | droplet-Lung-1m-Mesenchymal-myofibroblast-pericyte_cell|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.72e-04 | 184 | 37 | 3 | 39bb0eb55bdc2cea46e41c7f21d8c5883f14e6bd | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-monocyte|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.72e-04 | 184 | 37 | 3 | bc0dfe29337f02594e7e0092c9e47dda94b45ad5 | |
| ToppCell | droplet-Lung-1m-Mesenchymal-myofibroblast-pericyte_cell-pericyte|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.72e-04 | 184 | 37 | 3 | 4cb5f299dd7413e0be1ad7af817ee614b23a18ae | |
| ToppCell | LPS_only-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.72e-04 | 184 | 37 | 3 | 327ff3ac8d2fecdd5d242bdc34f0dfdb1c59a68b | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.79e-04 | 185 | 37 | 3 | 7092436b4db90289516ed130ade596e3021cffaf | |
| ToppCell | Control-Lymphocyte-T_NK-CD4_TEM|Control / Disease, Lineage and Cell Type | 4.79e-04 | 185 | 37 | 3 | 8d6a089dcb4bfb0e74b6316fb7221688c1835e6e | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.79e-04 | 185 | 37 | 3 | 51dfe6ac7df8b330343b37e3bee71e5c65267189 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-brain_pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.79e-04 | 185 | 37 | 3 | 38486b69c48dc5e1c4e1488208fa8954a973eccb | |
| ToppCell | P15-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 4.79e-04 | 185 | 37 | 3 | b1e84228c95be8ccf7c3c1afb66b71ffb93cf61e | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.79e-04 | 185 | 37 | 3 | a8c02cec3c414f3a0da9f2d6d28ce563b0030705 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-Pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.79e-04 | 185 | 37 | 3 | 3c28b5ceba3cfdb6f7e32d5b42e03b6a81a7a658 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.79e-04 | 185 | 37 | 3 | a8ca7819066d5297ef6966e7f3e2c9f8a7673fdc | |
| ToppCell | Healthy-MAIT|Healthy / disease group, cell group and cell class | 4.87e-04 | 186 | 37 | 3 | 028061f06d86e75cb06db56b199594b80f23fa58 | |
| ToppCell | droplet-Lung-nan-18m-Mesenchymal-Myofibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.87e-04 | 186 | 37 | 3 | cd6502bbf9dce318fdbb4965d49df8951e5f795c | |
| Drug | irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A | 1.12e-05 | 183 | 37 | 5 | 7498_DN | |
| Drug | Sulfaphenazole [526-08-9]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 1.18e-05 | 185 | 37 | 5 | 1673_DN | |
| Drug | Etidronic acid, disodium salt [7414-83-7]; Down 200; 16uM; MCF7; HT_HG-U133A | 1.28e-05 | 188 | 37 | 5 | 3325_DN | |
| Drug | Pregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A | 1.57e-05 | 196 | 37 | 5 | 2856_DN | |
| Drug | testosterone enanthate | 3.37e-05 | 575 | 37 | 7 | ctd:C004648 | |
| Drug | IAHS | 9.18e-05 | 9 | 37 | 2 | CID003037832 | |
| Drug | Succimer | 1.47e-04 | 1264 | 37 | 9 | ctd:D004113 | |
| Drug | Magnetite Nanoparticles | 1.93e-04 | 1310 | 37 | 9 | ctd:D058185 | |
| Drug | Etifenin [63245-28-3]; Down 200; 12.4uM; PC3; HT_HG-U133A | 1.95e-04 | 178 | 37 | 4 | 3998_DN | |
| Drug | Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A | 1.99e-04 | 179 | 37 | 4 | 4585_DN | |
| Drug | torcetrapib | 2.18e-04 | 342 | 37 | 5 | ctd:C483909 | |
| Drug | myxothiazol | 2.31e-04 | 14 | 37 | 2 | ctd:C030517 | |
| Drug | Neostigmine bromide [114-80-7]; Down 200; 13.2uM; PC3; HT_HG-U133A | 2.40e-04 | 188 | 37 | 4 | 6735_DN | |
| Drug | Chlorambucil [305-03-3]; Down 200; 13.2uM; PC3; HT_HG-U133A | 2.45e-04 | 189 | 37 | 4 | 3788_DN | |
| Drug | Deltaline [6836-11-9]; Down 200; 7.8uM; PC3; HT_HG-U133A | 2.50e-04 | 190 | 37 | 4 | 4306_DN | |
| Drug | Budesonide [51333-22-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 2.50e-04 | 190 | 37 | 4 | 2866_DN | |
| Drug | Flunisolide [3385-03-3]; Down 200; 9.2uM; PC3; HT_HG-U133A | 2.55e-04 | 191 | 37 | 4 | 4303_DN | |
| Drug | Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A | 2.55e-04 | 191 | 37 | 4 | 4279_DN | |
| Drug | Proguanil hydrochloride [637-32-1]; Down 200; 13.8uM; MCF7; HT_HG-U133A | 2.60e-04 | 192 | 37 | 4 | 3505_DN | |
| Drug | Carbamazepine [298-46-4]; Up 200; 17uM; PC3; HT_HG-U133A | 2.71e-04 | 194 | 37 | 4 | 1805_UP | |
| Drug | 5279552; Down 200; 22uM; MCF7; HT_HG-U133A_EA | 2.76e-04 | 195 | 37 | 4 | 843_DN | |
| Drug | Propylthiouracil [51-52-5]; Down 200; 23.4uM; HL60; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 2476_DN | |
| Drug | Riluzole hydrochloride; Down 200; 14.8uM; MCF7; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 4689_DN | |
| Drug | Sulfaphenazole [526-08-9]; Down 200; 12.8uM; PC3; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 1794_DN | |
| Drug | estradiol, USP; Down 200; 0.01uM; HL60; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 1182_DN | |
| Drug | Benzonatate [104-31-4]; Up 200; 6.6uM; PC3; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 1801_UP | |
| Drug | Chelidonine monohydrate (+) [476-32-4]; Down 200; 10.8uM; MCF7; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 6236_DN | |
| Drug | Thalidomide [50-35-1]; Down 200; 15.4uM; MCF7; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 2258_DN | |
| Drug | PNU-0293363 [326823-19-2]; Up 200; 10uM; PC3; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 6568_UP | |
| Drug | 2-propylpentanoic acid; Up 200; 200uM; MCF7; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 6934_UP | |
| Drug | wartmannin | 2.87e-04 | 811 | 37 | 7 | CID000005691 | |
| Drug | Hydrastinine hydrochloride [4884-68-8]; Up 200; 16.4uM; PC3; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 2119_UP | |
| Drug | DNA-PK Inhibitor III; Down 200; 1uM; MCF7; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 7543_DN | |
| Drug | Thalidomide [50-35-1]; Down 200; 15.4uM; PC3; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 2095_DN | |
| Drug | Ivermectin [70288-86-7]; Down 200; 4.6uM; MCF7; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 7206_DN | |
| Drug | Isoxsuprine hydrochloride [579-56-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 1485_UP | |
| Drug | Gentamicine sulfate [1405-41-0]; Down 200; 2.6uM; PC3; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 2082_DN | |
| Drug | Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; HL60; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 2560_DN | |
| Drug | clozapine; Down 200; 10uM; HL60; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 1170_DN | |
| Drug | Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; PC3; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 4343_UP | |
| Drug | wortmannin from Penicillium funiculosum; Down 200; 0.01uM; HL60; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 1184_DN | |
| Drug | PHA-00851261E [724719-49-7]; Up 200; 1uM; PC3; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 4333_UP | |
| Drug | (-)-Cinchonidine [485-71-2]; Up 200; 13.6uM; HL60; HG-U133A | 2.98e-04 | 199 | 37 | 4 | 1780_UP | |
| Drug | 0317956-0000 [391210-11-0]; Up 200; 1uM; PC3; HT_HG-U133A | 2.98e-04 | 199 | 37 | 4 | 4334_UP | |
| Drug | Moxisylyte hydrochoride [964-52-3]; Up 200; 12.6uM; HL60; HT_HG-U133A | 3.04e-04 | 200 | 37 | 4 | 1846_UP | |
| Drug | geldanamycin | 3.17e-04 | 371 | 37 | 5 | ctd:C001277 | |
| Disease | Antihypertensive use measurement | 1.94e-05 | 265 | 37 | 5 | EFO_0009927 | |
| Disease | aspartate aminotransferase measurement, serum alanine aminotransferase measurement, low density lipoprotein triglyceride measurement, body fat percentage, high density lipoprotein cholesterol measurement, sex hormone-binding globulin measurement | 8.76e-05 | 364 | 37 | 5 | EFO_0004612, EFO_0004696, EFO_0004735, EFO_0004736, EFO_0007800, EFO_0009946 | |
| Disease | vital capacity | 1.21e-04 | 1236 | 37 | 8 | EFO_0004312 | |
| Disease | body fat percentage | 3.41e-04 | 488 | 37 | 5 | EFO_0007800 | |
| Disease | nephrosis (biomarker_via_orthology) | 3.48e-04 | 22 | 37 | 2 | DOID:2527 (biomarker_via_orthology) | |
| Disease | Grey matter density measurement | 8.37e-04 | 34 | 37 | 2 | EFO_0010306 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| METIVMQENNEQTDT | 1471 | A6H8Y1 | |
| ENMKSEMAQIQQNAV | 106 | Q15389 | |
| TDMVQMIFSNNADQQ | 86 | O15131 | |
| ENQHMQMTIQALQDE | 221 | Q8IUD2 | |
| GSIMENEQRSNQMNN | 221 | Q5JS13 | |
| ITMQNQLQQNMQEGL | 956 | Q86WG5 | |
| DAIMNMQDNSVQVSQ | 321 | O75487 | |
| SNQAEDQDVQMMNEN | 1571 | O60303 | |
| DQDVQMMNENQIITN | 1576 | O60303 | |
| SQQNQMLLEQNMENK | 1346 | Q9P219 | |
| QKMQEQQMQEQAAQL | 541 | Q96PP8 | |
| TVANNGMNNNMSLQD | 316 | P27986 | |
| QQQQQQQQVMESSAA | 881 | O94916 | |
| MSALQTSINQQDMQQ | 1381 | O94916 | |
| AEEMQIQNTQLMNGS | 291 | Q86Y26 | |
| MSLSLEQQMQQRQQQ | 896 | Q96JP2 | |
| MTNASNSQQSISMQQ | 216 | Q3L8U1 | |
| VNLMNASNDITMENV | 596 | Q6YHK3 | |
| QNQQLQAQMTEMEQA | 1556 | H7BZ55 | |
| QNPQEVMMNSSNIQV | 71 | P16671 | |
| QAQLQEQQVQVEMDM | 251 | P17661 | |
| MLQENSELMNNNSSE | 411 | Q5VWK5 | |
| MNLEEQSQQQENLML | 266 | O60266 | |
| QNQNTRQQMDTPMVS | 556 | O43303 | |
| MYNQEQQENSAESMQ | 266 | Q14995 | |
| GAQSEQKNNSMNSNM | 126 | Q96AH0 | |
| IDQLMNQMQQIETQQ | 711 | Q9UQE7 | |
| QQQQLTNLQMAAVTM | 91 | Q9UHX1 | |
| MNIMNTEQSQNSIVS | 1 | Q5HYK7 | |
| QSPSFNSMMNQMNQQ | 1131 | Q9Y6Q9 | |
| MQEQQKSLDIGNQMN | 616 | Q6P3W7 | |
| QHINMTSQQCTNAMQ | 41 | P10153 | |
| TCMSEETSNQKQQQQ | 326 | Q14119 | |
| QQVMTTVQNMQHESA | 1226 | Q15643 | |
| DQQSMQASTQMQVEI | 786 | Q9UL36 | |
| QMIMENQNSENTAQV | 191 | Q9BXG8 | |
| QDEMVSTKQQNNTSQ | 261 | O43164 | |
| NMMLLQQNMTQIQHN | 831 | Q15911 | |
| QQNEKEMMEQIRQQT | 1506 | B2RTY4 | |
| AMETDITEQQQAAMQ | 2316 | B2RTY4 |